{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Membrane Transporter & Ion Channel > DapagliflozinCAS：461432-26-8
Molecular Formula：C21H25ClO6
Molecular Weight：408.87
Storage：Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥97%
Appearance：White to yellow Solid
Qty：
Size：
| CAS | 461432-26-8 |
| Name | Dapagliflozin |
| Molecular Formula | C21H25ClO6 |
| Molecular Weight | 408.87 |
| Solubility | Soluble in DMSO ≥10mg/mL;Soluble in Ethanol ≥25mg/mL |
| Purity | HPLC≥97% |
| Appearance | White to yellow Solid |
| Storage | Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 639-683-0 |
| MDL | MFCD13182359 |
| SMILES | O[C@H]1[C@H](C2=CC(CC3=CC=C(OCC)C=C3)=C(Cl)C=C2)O[C@H](CO)[C@@H](O)[C@@H]1O |
| Target Point | SGLT |
| Passage | Membrane Transporter&Ion Channel |
| Background | Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. |
| In Vitro | Dapagliflozin预处理缺氧HK2细胞以剂量依赖性方式显著改善细胞活力。 Dapagliflozin可降低缺氧HK2细胞中Bax的表达，Bax/Bcl2比值和PARP的表达[2]。 |
| In Vivo | 在11mM葡萄糖时，达格列嗪将胰高血糖素释放从对照的18％提高至32％，而达格列嗪在1mM葡萄糖时的添加效果较小。在中等葡萄糖浓度为6mM时，在不存在或存在达格列嗪的情况下，胰高血糖素分泌估计分别为对照的24％和30％[1]。 Dapagliflozin预处理显著减少IR损伤肾脏中TUNEL阳性细胞的数量。 Dapagliflozin预处理显著提高小鼠IR损伤的肾小管细胞中HIF1的表达[2]。 Dapagliflozin(10 mg/kg，op)引起SGLT2i小鼠尿糖的显著增加。 Dapagliflozin通过减少交感神经活动来急剧抑制BAT产热。 Dapagliflozin可增强肝脏糖异生和糖原分解[3]。 |
| Cell Experiment | 为了进行细胞存活测定，在用载体或达格列嗪预处理在30分钟缺血中孵育24小时后收集细胞，并用台盼蓝染色计数存活细胞。通过量化相对存活的处理细胞数除以未处理细胞的存活数来确定存活百分比。 |
| Animal Experiment | 将体重30-33g的10周龄雄性C57BL/6小鼠分成5组：载体(Vh)处理的假(n = 5)，达格列嗪处理的假(n = 5)，Vh处理的IR(n = 7)，达格列嗪处理的IR(n = 7)，和阿苯达唑和达格列嗪处理的IR(n = 7)。在手术前24小时开始，通过口服强饲法以10mg/kg /天的剂量给予达格列嗪2天。在IR手术前1小时皮下注射阿苯达唑。 |
| Data Literature Source | [1]. Pedersen MG，et al. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci Rep. 2016 Aug 18;6:31214. [2]. Yoon-Kyung Chang，et al. Dapagliflozin，SGLT2 Inhibitor，Attenuates Renal Ischemia-Reperfusion Injury. PLoS One. 2016; 11(7): e0158810. [3]. Chiba Y，et al. Dapagliflozin，a Sodium-Glucose Co-Transporter 2 Inhibitor，Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice. PLoS One. 2016 Mar 10;11(3):e0150756. [4]. Akahane K，et al. Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats. Drug Res (Stuttg). 2015 Aug;65(8):416-21. [5]. Sakaeda T，et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018 Jun 13;15(9):937-943. |
| Unit | Bottle |
| Specification | 10mg 10mM*1mL in DMSO 50mg 100mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
